An unfunded A0 application is not the end. It is a structured consultation with expert reviewers, delivered free, that most PIs ignore entirely. This post explains why A1 resubmissions succeed at a much higher rate than new submissions, how to read the feedback you actually got (rather than the feedback you think you got), and how to respond in a way that moves reviewers from skeptical to convinced.
The most effective resubmissions change 30–40% of the text but address 100% of the concerns. The conceptual framework stays. The execution strengthens everywhere.
The resubmission advantage is real but conditional
An NIH A1 (Type 2) application — a resubmission of an unfunded A0 — succeeds at rates of 20–30 percent. That is roughly double the success rate for new A0 submissions, which hover around 11–15 percent in a typical fiscal year. The advantage is large enough that a PI who receives a summary statement has a real choice to make: revise and resubmit, or start fresh with a new idea.
But the advantage is not automatic. A perfunctory resubmission — one that acknowledges the reviewer critiques with a word or two and makes cosmetic changes — will perform no better than a new application, and sometimes worse, because reviewers can see that you did not take their feedback seriously. Conversely, an A1 that addresses every critique with new data, new collaborators, or clearer logic will often jump 10–20 percentile points from the original A0 score.
The threshold for success is not "respond to every critique." It is "respond to every critique in a way that shows you understood what went wrong and how to fix it."
Reading the summary statement: What reviewers actually said versus what they think they said
The summary statement has two parts that matter for resubmission strategy: the Resume and Summary of Discussion (if the application was discussed), and the individual reviewer critiques that follow.
The resume and summary of discussion: Where the consensus lives
If your application made it to discussion at the study section, the summary statement will include a brief resume of what the panel talked about. This resume is the closest thing you have to a consensus view: it reflects the issues that enough reviewers flagged that the panel took time to debate them.
The resume typically lists two to four "score-driving factors" — the specific concerns that moved the needle on your priority score. These are the things you must address in the A1. Ignore them and you will probably fail again.
In contrast, if your application was triaged (streamlined), there is no resume. You only receive the individual reviewer critiques. Triaged applications are harder to resubmit successfully because you have to infer where the consensus actually was, rather than reading it plainly. More on that below.
Individual reviewer critiques: Consensus signals
The three assigned reviewers each write a critique. Read all three, not just the harshest one. If all three reviewers raised the same concern about your specific aims, that is a consensus signal — you must address it. If only one reviewer questioned your preliminary data and the other two praised it, that is a dissenting signal — you can acknowledge it, but you do not need to fundamentally redesign that section.
Many PIs spend more time defending themselves against outlier critiques than addressing consensus problems. Resist this urge. Consensus concerns are why your score dropped. Outlier concerns are noise.
Because study section rosters rotate every three years, there is no guarantee that your A1 will be reviewed by the same panel as your A0. However, all A1 reviewers will see your original summary statement. This means a new reviewer who did not see your A0 is seeing a document that summarises the prior panel's concerns — sometimes in language that oversimplifies the original critique. Reading the three individual reviewer critiques carefully, rather than relying only on the resume, gives you the full picture that the new reviewer will be working from. And if you address the nuances in the original critiques, you will be prepared for different interpretations in the new panel.
The introduction to resubmission: One page to address everything
The Introduction to Resubmission is your one chance to show that you listened and understood. It should be exactly one page (no exceptions — NIH checks). The standard structure is straightforward:
- Acknowledge the critique. State what the reviewers said in your own words. Do not quote verbatim. Show that you understood the concern beneath the words.
- State the change you made. What specifically did you do to address this? New data? New collaborator? Revised approach? Be concrete.
- Point to where the change appears in the proposal. "See page 3 of the Research Strategy, second paragraph" or "See the new Figure 2 in the Significance section."
The tone should be constructive, not defensive. You are not arguing. You are problem-solving alongside the reviewer. If you find yourself writing words like "we respectfully disagree" or "our original approach is actually correct," you have already lost the resubmission. Delete that section and reframe it as a data problem or a clarity problem instead.
When you disagree with a reviewer: Provide evidence, never argument
Occasionally a review comment will be wrong or misguided. A reviewer may have misread your aims, or missed a key paper, or made a logical error in their critique. The instinct to correct them is strong. Resist it entirely.
Instead, ask yourself: What would new evidence look like? If the reviewer doubted the feasibility of your approach, show them new preliminary data, or bring on a collaborator with a track record of success in the same approach, or detail a risk mitigation strategy that preempts the concern. If the reviewer missed a key paper, revise your literature review to make that paper central rather than peripheral — make it impossible to miss.
If you provide only logical argument without new evidence, reviewers will interpret this as defensiveness. You will damage your credibility on the sections where you did change. So do not argue. Show new ground.
What to change and what to preserve
The most effective resubmissions are not comprehensive rewrites. They are surgical revisions. The rule of thumb: change 30–40 percent of the text, but address 100 percent of the concerns.
Your conceptual framework — the basic scientific question you are asking, the general approach, the specific aims as stated — should survive the resubmission largely intact. This continuity is important: it shows that you are not abandoning the idea in response to criticism, but strengthening it.
Where you change aggressively: the execution details. The preliminary data section. The methods. The risk mitigation. The timeline. The evidence that you can actually do what you say you will do. If a reviewer questioned your approach, you revise the approach section until it is airtight. If they questioned your timeline, you revise the timeline with new justification. If they wanted more preliminary data, you add it (or explain why you cannot and how you will manage that risk).
The introduction and background stay relatively stable — but if a reviewer showed that they misunderstood a key concept, you rewrite that paragraph to be clearer. Not longer, clearer. Do not defend the clarity; improve it.
The introduction to the resubmission in practice: An example
Here is what a strong response looks like (abbreviated for space):
Reviewer concern: The preliminary data are insufficient to support the claim that X pathway is rate-limiting in this disease. The two experiments shown are from a single cell line. This needs population-level data. PI response in Introduction: We thank the reviewers for this critique. The prior submission presented in vitro data from a single model system. We have now completed three additional experiments (described in the new Figure 2, page 5 of the Research Strategy): quantitative measurement of X activity in primary patient cells from 12 subjects with the disease phenotype, and in 8 healthy controls, showing a significant difference (p < 0.01). These data directly address the concern about generalisability and provide the population-level evidence the panel requested. We have revised the Approach section (page 6, paragraph 2) to incorporate these findings as the justification for why this mechanism is rate-limiting, and to outline how our proposed experiments will extend this observation to disease progression.
Notice what this does right: it acknowledges the critique specifically, describes the new work in concrete detail, and points the reviewer to the exact location where they can verify the change. It does not argue that the original data were sufficient. It shows new ground.
Strategic use of the A0–A1 cycle: The free consultation model
Some experienced PIs approach the first submission strategically. They submit a competent but not-yet-optimised A0, knowing it will not be funded but will generate expert feedback. They then use the summary statement as a structured consultation to identify the gaps. The new preliminary data they generate between A0 and A1 becomes the strongest evidence in the resubmission.
This strategy works. It treats the summary statement as what it actually is: unpaid expert review that would cost thousands of dollars if you paid a grant-writing consultancy for the same feedback. But it only works if you can generate genuinely new data between submissions. If you cannot, you are wasting the resubmission opportunity.
The virtual A2: When (and when not) to submit as a new A0
In 2009, the NIH eliminated the second resubmission — you can only resubmit once. If your A1 is not funded, you cannot submit another amendment. You must either stop or submit a substantially revised new A0 application, which will be evaluated as a de novo submission.
This path is sometimes called a virtual A2. It carries no resubmission advantage. Data from the NIH Allergy and Infectious Diseases Institute show that virtual A2 applications fund at essentially the same rate as genuine new A0 submissions — no higher, but also no lower. The prior submission history is not a penalty; it just is not an advantage either.
So when should you submit a virtual A2? Only when the unfunded A1 genuinely failed because you lacked preliminary data or key collaborators, and you have since acquired them. The virtual A2 must be substantially different from the A1 — different enough that it reads as a new idea rather than a third attempt at the old one. If it reads like you are just trying again, it will score lower because reviewers will assume you have not learned anything from the feedback.
If your A1 was triaged or scored very poorly, or if the study section feedback suggests the project is not viable, a virtual A2 is unlikely to succeed. In these cases, a completely new proposal with a different mechanism or aim is often a better bet.
When not to resubmit: The hard cases
Not every summary statement warrants a resubmission. Consider passing on the A1 if any of the following is true:
- The application was triaged and the individual critiques point to conceptual problems. Triaged applications are those that reviewers found noncompetitive relative to the full pool. If the feedback suggests fundamental issues with the scientific approach rather than execution gaps, the bar for a successful A1 is very high. You may have better luck with a new A0 using a different approach.
- The study section was a poor fit and feedback shows misunderstanding. If multiple reviewers misinterpreted your work or seemed to lack expertise in your subfield, request reassignment to a different study section — or submit a new A0 to the more appropriate section without the "resubmission" label. You lose the resubmission advantage, but you also lose the baggage of being in the wrong room.
- You now have preliminary data that makes the original approach obsolete. If your first submission was based on preliminary data from Year 1 of a pilot study, and that study has now been completed, you may want to submit a new A0 with the updated findings rather than resubmit the old framework. The new data are powerful enough that starting fresh is worth considering.
- The budget constraints make the approach infeasible. If the study section's feedback hinges on concerns about feasibility and you do not have access to new funding or resources, resubmission is unlikely to succeed. Address the constraint directly with a program officer before deciding whether to proceed.
Timeline and administrative details
You have 37 months from the original submission date to submit the A1. After that window closes, the resubmission mechanism expires and any new submission must be a new A0.
Most PIs aim to resubmit at the next available receipt date, typically three to four months after the summary statement arrives. This gives you time to generate preliminary data and revise without losing momentum. However, there is no penalty for waiting — if you need a full year to generate the new data that will make the A1 competitive, take it. A strong resubmission submitted late is better than a weak one submitted quickly.
When you submit, you will include the prior summary statement and your Introduction to Resubmission in the application package. NIH provides a cover letter template for resubmissions. Use it.
A resubmission checklist
Before you start revising
- Read all three reviewer critiques at least twice. Highlight consensus concerns and dissenting comments separately.
- Speak with your program officer. Ask specifically: does the feedback suggest the work is fundable with revisions, or are there fundamental concerns that resubmission cannot address?
- Identify the "score-driving factors" from the resume. These are your North Star for the revision. Everything else is secondary.
- Make a list of what new evidence, collaborators, or methods you can realistically add before the next receipt date.
- Decide: is the research likely to be more fundable in A1 form, or would a fresh A0 with a different approach be more strategic?
Writing the Introduction to Resubmission (one page only)
- Address every substantive critique from every reviewer. Omitting a critique signals that you did not take it seriously.
- Use the structure: Acknowledge → Change → Location. No other pattern is as clear.
- For each point, be specific about what is new. "We have strengthened the preliminary data" is vague. "We completed quantitative RNA-seq analysis of the three key genes" is concrete.
- If you disagree with a critique, provide new evidence, never argument. If you cannot generate new evidence, acknowledge the concern and explain how you will manage the risk.
- Bold or italicise all page numbers and figure references so reviewers can find the changes without hunting.
Revising the Research Strategy
- Track changes in the full proposal text (use the redline feature in Word or equivalent). Reviewers want to see what changed and what stayed the same.
- Update the Significance section if new literature or preliminary data strengthens the rationale.
- Revise the Approach section to address feasibility concerns. Add new methods, collaborators, preliminary data, risk mitigation, or timeline detail as needed.
- If a reviewer questioned your Specific Aims, reword them for clarity without changing the scientific substance.
- Ensure that all changes in the Introduction to Resubmission can be verified by reading the proposal. If you claim to have added new preliminary data, that data must appear in a figure or table.
Preparing to submit
- Check the submission deadline. A1s are due at the same dates as A0s — you do not get a separate submission window.
- Ensure that the prior summary statement is included in the package (NIH often does this automatically through eRA Commons).
- Include the Introduction to Resubmission using the standard cover letter template. Do not bury it — it should be the first page of narrative the reviewer sees.
- If you are requesting a study section reassignment, submit the Assignment Request Form with your application.
- Format-check the entire application for compliance before submission. A formatting error will delay review and may trigger a return without review.
The hidden advantage of A1 resubmission
The statistical advantage — 20–30 percent success rate versus 11–15 percent for new submissions — is real and worth pursuing. But the deeper advantage is softer and harder to measure: you now have feedback from expert reviewers on exactly what moved the needle. A new A0 submission comes blind. An A1 comes with a map.
PIs who use that map — who read the feedback as data about how their proposal was perceived rather than as a indictment of the science itself — almost always improve their score. PIs who argue with the feedback almost always fail the resubmission.
The choice is yours. But the odds are in your favour if you choose to listen.
Frequently asked questions
How long do I have to submit an A1 resubmission?
You must submit a resubmission within 37 months of the original unfunded application. If you do not resubmit within this window, the application is considered lapsed and you must submit a new A0 application. The resubmission mechanism persists — it does not expire — but NIH will track the original submission date. Note that you can only resubmit once: an unfunded A1 cannot be amended again. If you wish to resubmit after an unfunded A1, you must submit as a new A0 (virtual A2) with substantial revisions.
Will my A1 be assigned to the same reviewers as my A0?
Not necessarily. Study section rosters rotate and reviewers move on and off every three years. However, all A1 reviewers will receive the prior summary statement and will see your Introduction to Resubmission. Even if some reviewers are new, they have access to the prior feedback and can see what concerns you are addressing. This is actually an advantage: new reviewers can sometimes see merit that the original panel missed, especially if the prior summary statement contained idiosyncratic concerns.
What if I disagree with a reviewer critique?
Never argue against a critic in the Introduction to Resubmission. Instead, provide new evidence or new reasoning. If a reviewer questioned the feasibility of your approach, do not defend your original plan — show new preliminary data, add a new collaborator, or add a risk mitigation strategy that addresses their concern in substance rather than tone. If you provide only a counterargument without new evidence, reviewers interpret this as defensiveness and it damages your credibility on other sections.
Is a triaged application worth resubmitting?
Triaged (streamlined) applications were not discussed at the study section meeting, which means reviewers considered them noncompetitive relative to the pool. These are harder to resubmit successfully because the reasons for the low score are less detailed. If the individual reviewer critiques point to addressable conceptual issues, resubmission is worth considering. If the feedback suggests fundamental problems with the project or study section mismatch, you may have better success submitting a new A0 with a completely revised framing to a different study section, which avoids the perception that you are defending a rejected idea.
Can I change study sections between A0 and A1?
Yes. You can request a change in study section assignment using the Assignment Request Form included with your resubmission application. Note that requesting reassignment also carries a small risk: if you move to a less appropriate study section, the new panel may have less expertise in your work. Generally, request reassignment only if there is a clear mismatch between your work and the original study section, or if the original panel's feedback indicates they fundamentally misunderstood your approach.
Get the full 115-point audit for your paper or preprint
Whether you are preparing an NIH resubmission or seeking to improve the discoverability of your published work, the Academic SEO 115-point audit identifies every structural, technical, and metadata gap that keeps your research from reaching its audience.
Request an audit